Wall Street Thinks Rocket Lab Is a Buy. Here's Why I'm Not So Sure.

Rocket Lab reported record quarterly revenue, up 62% year over year, and backlog exceeding $2.3 billion, but its operating expenses reached $142 million in Q2 and $274 million in the first half, underscoring continued losses and elevated cash burn. The Neutron rocket's inaugural launch, initially expected in 2025 and most recently targeted for Q4 2026, may slip to 2027, pushing profitability further out. The company also faces integration risk from two completed 2026 acquisitions and a pending Iridium Communications transaction, while shares trade near 50x sales despite falling more than 50% from their $151 peak.

Analysis

RKLB’s equity story is increasingly a duration trade: a further delay in Neutron shifts the highest-margin, vertically integrated launch opportunity out while development and integration costs remain current. At an extreme revenue multiple, even modest downward revisions to first-launch timing, annual launch cadence, or post-launch cash burn can drive disproportionate multiple compression; the relevant risk is not a weak quarter but a reset in the market’s assumed 2028-29 free-cash-flow profile.

The second-order beneficiary of delayed medium-lift capacity is SpaceX, which can retain pricing leverage in dedicated launches and rideshare allocation, while defense primes such as LMT and NOC remain better positioned for mission-critical customers unwilling to accept schedule uncertainty. RKLB’s existing Electron and space-systems franchises provide operational credibility, but they do not eliminate the financing risk if development spend persists beyond the currently implied runway; dilution, rather than demand, is the principal 6-18 month equity risk.

Consensus appears anchored to backlog growth and the strategic scarcity value of an alternative U.S. launch provider. That misses that backlog conversion may be less valuable if customers defer, reprice, or migrate missions as launch timing moves. Conversely, the short thesis is vulnerable to a credible Neutron static-fire/qualification milestone, a major defense award with funded economics, or evidence that acquired assets improve space-systems gross margin rather than add overhead.

The reported IRDM transaction should not be traded from this item alone: transaction structure, consideration, regulatory conditions, and pro forma leverage are absent. Confirm whether it is a signed definitive agreement and whether consideration is cash, stock, or contingent before inferring either accretion or integration risk.

Key Decisions for Investors

• Maintain a tactical underweight/short RKLB over the next 1-3 months, preferably via a 3-6 month put spread rather than naked short exposure; target a 20-30% downside on a launch-timeline or cash-burn reset, with risk defined by a verified Neutron qualification milestone or major funded defense contract.
• For a lower-beta expression, pair short RKLB against long ITA or a basket of LMT/NOC over 6-12 months. The trade isolates execution-duration risk while retaining exposure to rising U.S. space and defense budgets; reassess if RKLB demonstrates improving consolidated gross margin alongside unchanged capex guidance.
• Do not initiate an IRDM position until definitive deal terms are verified. Set an alert for exchange ratio/cash consideration, breakup provisions, and expected closing date; a stock-funded transaction would create a different arbitrage and dilution setup than a cash transaction.
• Monitor the next earnings release for operating-cash-flow guidance, capex, share issuance/ATM activity, and Neutron schedule specificity. Any increase in projected burn or movement of first launch beyond the stated window is a catalyst to add to the RKLB downside; unchanged timing plus a funded customer commitment would invalidate the near-term short.